Change Is the Cure�, BeiGenes ESG strategy and framework launched in 2021, defines the Companys aspirational reason for thinking beyond its products and provides a path to help create a better world
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$BGNE #BTKi—BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today introduced the Companys global environmental, social, and governance (ESG) strategy.
At BeiGene, we are driven by our mission to be a transformational company that addresses global health needs and inequities by making innovative medicines more affordable and accessible, said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. As an industry, we know that we must do better. At BeiGene, this means striving for more efficient ways to develop new therapies, deliver them more broadly, and do so in a way that mitigates our impact on the planet.
Over the past year, BeiGene formalized its ESG function and defined the Companys new global ESG strategy and framework, Change Is the Cure. Designed to address the needs of BeiGenes diverse stakeholders, this framework includes five focus areas and defines strategic priorities:
While we are just beginning our ESG journey, we are proud of the progress we have made in the past year, including completing our first global carbon footprint analysis across our owned and operated facilities and implementing a new Supplier Code of Conduct, said Christine Riley Miller, ESG Lead at BeiGene. We have also defined near-term targets for fiscal year 2022 that will set the foundation for building long-term goals.
Below are select highlights from BeiGenes 2021 ESG report, which was developed with reference to Global Reporting Initiative (GRI) standards:
View the full BeiGene 2021 ESG Report here: https://www.beigene.com/PDF/2021-ESG-Report.pdf.
About BeiGene
BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 8,000 colleagues across five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGenes plans, commitments, aspirations and goals for ESG as well as under the heading About BeiGene. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing and other services; BeiGenes limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates and achieve and maintain profitability; the impact of the COVID-19 pandemic on BeiGenes clinical development, regulatory, commercial, manufacturing and other operations, as well as those risks more fully discussed in the section entitled Risk Factors in BeiGenes most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
Contacts
Investor
Kevin Mannix
+1 240-410-0129
ir@beigene.com
Media
Emily Collins
+1 201-201-4570
media@beigene.com
BANGALORE, India--(BUSINESS WIRE)--$WIPRO #AdditiveManufacturing--Wipro Hydraulics, the hydraulic cylinders and components manufacturing business of Wipro Infrastructure…
DUBLIN--(BUSINESS WIRE)--The "Nanocomposites - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.…
NOIDA, India--(BUSINESS WIRE)--#AI--R Systems International Limited (a Blackstone portfolio company), a leading digital product engineering…
Masahiro Minowa Appointed Representative Director and CEO following resignation of Gordon Raison LOS ANGELES--(BUSINESS WIRE)--Roland…
DUBLIN--(BUSINESS WIRE)--The "Adipic Acid - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.…
HONG KONG SAR - Media OutReach Newswire - 9 May 2024 - Generali Hong Kong…